홈 > 시장보고서 > 의약품 > 암

시장보고서

상품코드

1289780

세계의 T세포 림프종 시장(2023-2030년)

Global T-Cell Lymphoma Market - 2023-2030

발행일: 2023년 06월 | 리서치사:

DataM Intelligence | 페이지 정보: 영문 195 Pages | 배송안내 : 1-2일 (영업일 기준)

■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

시장 개요

T세포 림프종 시장은 2022년 14억 8,520만 달러에 달하며, 2030년에는 최대 27억 8,780만 달러에 달하며 유리한 성장을 보일 것으로 예상되며, T세포 림프종 시장은 예측 기간(2023-2030년) 동안 8.4%의 CAGR을 나타낼 것으로 예상됩니다.

T세포 림프종은 말초 T세포 림프종과 T세포 림프 모세포 림프종의 두 가지 유형으로 나뉘며, T세포 림프종은 화학요법, 방사선 요법, 면역 요법, 항바이러스제, 줄기세포 이식 및 기타 치료법으로 치료할 수 있습니다.

또한 T세포 림프종 시장의 성장은 방사선에 의한 림프종 암 발생률 증가, T세포 림프종 특이적 치료법 증가, 자가면역질환으로 인한 림프종 위험성 등이 원인으로 작용하고 있습니다.

시장 역학

세계의 암 유병률 증가

암 유병률 증가는 T세포 림프종 시장 기회에 영향을 미치는 촉진요인 중 하나입니다. 또한 의료 인프라에 대한 투자 증가와 노인 인구 증가도 T세포 림프종 시장 확대에 영향을 미치는 요인 중 하나입니다.

WHO에 따르면 암은 세계 주요 사망 원인으로 2020년에는 약 1,000만 명, 즉 6명 중 1명이 암으로 사망할 것으로 추정됩니다. 매년 약 40만 명의 어린이가 암에 걸립니다. 가장 흔한 암은 국가마다 다르다.

높은 치료비용과 긴 치료기간

T세포 림프종 치료는 그 독특한 작용기전으로 인해 매우 고가이며, 회수 및 제조 과정도 총 비용에 추가됩니다. 또한 치료비용의 고비용은 환자의 기준에 따른 질병의 수준과 필요한 치료의 수준에 따라 환자마다 다르다.

COVID-19의 영향 분석

COVID-19 전염병은 암 치료 서비스의 혼란과 암 치료를 위한 임상시험 중단으로 인해 예측 기간 중 세계 T세포 림프종 시장 동향에 부정적인 영향을 미쳤습니다.

COVID-19로 인해 피부림프종 환자들은 병원 접근이 어렵거나 가용한 의료 자원이 부족하여 중요한 진단 검사와 치료를 받지 못할 위험이 높아졌습니다.

Market Overview

The T-Cell Lymphoma Market reached US$ 1,485.2 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 2,787.8 million by 2030. The T-cell lymphoma market is expected to exhibit a CAGR of 8.4% during the forecast period (2023-2030).

T-cell lymphoma is classified into two types: peripheral T-cell lymphoma and T-cell lymphoblastic lymphoma. T-cell lymphoma can be treated with chemotherapy, radiotherapy, immunotherapy, antiviral medication, stem cell transplantation, and other therapies.

The growth of the T-cell lymphoma market is also attributed to the rise in lymphoma cancer incidence due to radiation, an increase in the number of T-cell lymphoma-specific therapies, and the risk of lymphoma due to autoimmune disorders.

Market Dynamics

Increase in Prevalence of Cancer Worldwide

The increase in the prevalence rate of cancer is one of the drivers that affect the T Cell lymphoma market opportunities. Another factor is increasing investment in healthcare infrastructure and the rising geriatric population that leads to the expansion of the T-cell lymphoma market.

According to WHO, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. Each year, approximately 400,000 children develop cancer. The most common cancers vary between countries.

High Cost and Long Duration of Treatment

Treatment for T-cell lymphoma is very expensive because of its unique mechanism of action and the collections and manufacturing processes also add to the total costs. The high cost of the treatment also varies from patient to patient according to the level of disease and level of treatment required as per the patient standards.

COVID-19 Impact Analysis

The COVID-19 pandemic had a negative impact on the global T-cell lymphoma market trend over the projection period, owing to disruptions in cancer treatment services and the halt of clinical trials for cancer therapy.

Due to the COVID-19 epidemic, patients with cutaneous lymphomas were at an increased risk of missing receiving crucial diagnostic tests and treatments, either because hospitals were difficult for them to access or because of a lack of available healthcare resources.

Segment Analysis

The Chemotherapy Segment will Dominate the Market in the Forecast Period with around 40.8% Market Share

Chemotherapy is a common treatment for T-cell lymphoma because it inhibits and slows the proliferation of cancer cells. In addition to surgery and radiation therapy, chemotherapy can affect the entire body. These treatments can destroy or eliminate cancer cells in a specific area of the body.

Also, a combination chemotherapy regimen, such as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), CHOEP (etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisone), or other multidrug regimens, is frequently used for treatment.

Geographical Analysis

North America is the Dominating Region During The Forecast Period Accounting For 42.4% In The Overall Market

The global T-cell lymphoma market is large in the North American region due to the high number of cases of T-cell lymphoma, the presence of strong rivals, and increased research in the North American region. Also, T-cell lymphomas are a subtype of Non-Hodgkin lymphoma and a rise in Non-Hodgkin lymphoma cases would likely increase the demand for new treatment options, assisting the market's growth.

Competitive Landscape

The major global players include: Johnson & Johnson, Novartis AG, Bristol Myers Squibb Company, Merck & Co Inc, F.Hoffmann La Roche Ltd, Acrotech Biopharma, GlaxoSmithKline Plc, and Spectrum Pharmaceuticals.

Why Purchase the Report?
To visualize the global T-cell lymphoma market segmentation based on the type, end user and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of global T-cell lymphoma market level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.

The global T-cell lymphoma market report would provide approximately 92 tables, 108 figures and 195 pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Type
3.2. Snippet by Treatment
3.3. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increase in the prevalence of cancer worldwide
- 4.1.2. Restraints
  - 4.1.2.1. High cost and long duration of treatment
- 4.1.3. Opportunity
  - 4.1.3.1. Rise in the investments and research funding of T-cell lymphoma market
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Drug Class

7.1. Peripheral T Cell Lymphoma
7.2. Cutaneous T Cell Lymphoma
7.3. Anaplastic Large Cell Lymphoma
7.4. Others

8. By Treatment

8.1. Radiotherapy
8.2. Chemotherapy
8.3. Targeted Therapy
8.4. Surgery
8.5. Stem Cell Transplantation
8.6. Others

9. By Region

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.2.5.1.1. The U.S.
  - 9.2.5.1.2. Canada
  - 9.2.5.1.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.3.5.1.1. Germany
  - 9.3.5.1.2. The UK
  - 9.3.5.1.3. France
  - 9.3.5.1.4. Italy
  - 9.3.5.1.5. Spain
  - 9.3.5.1.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.4.5.1.1. Brazil
  - 9.4.5.1.2. Argentina
  - 9.4.5.1.3. Rest of South America
9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.5.5.1.1. China
  - 9.5.5.1.2. India
  - 9.5.5.1.3. Japan
  - 9.5.5.1.4. Australia
  - 9.5.5.1.5. Rest of Asia-Pacific
9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Company Profiles

11.1. Johnson & Johnson
11.2. Novartis AG
11.3. Bristol Myers Squibb Company
11.4. Merck & Co Inc
11.5. F.Hoffmann La Roche Ltd
11.6. Acrotech Biopharma
11.7. GlaxoSmithKline Plc
11.8. Spectrum Pharmaceuticals

LIST NOT EXHAUSTIVE

12. Appendix

12.1. About Us and Services
12.2. Contact Us

02-2025-2992
(주말 및 공휴일 제외)

라이선스 / 가격

PDF & Excel (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,350

￦ 6,294,000

PDF & Excel (Multiple User License)

PDF 보고서를 동일 사업장에서 7명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,850

￦ 7,017,000

PDF & Excel (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 7,850

￦ 11,358,000

※ 부가세 별도

세계의 T세포 림프종 시장(2023-2030년)

Global T-Cell Lymphoma Market - 2023-2030

시장 개요

시장 역학

세계의 암 유병률 증가

높은 치료비용과 긴 치료기간

COVID-19의 영향 분석

목차

제1장 조사 방법과 범위

제2장 정의와 개요

제3장 주요 요약

제4장 시장 역학

제5장 산업 분석

제6장 COVID-19의 분석

제7장 약효 분류별

제8장 치료별

제9장 지역별

제10장 경쟁 구도

제11장 기업 개요

제12장 부록